3648-78-0

Basic information

• Product Name: 4-(4-Methoxyphenyl)tetrahydro-2H-pyran-4-carbonitrile
• Synonyms: 4-(4-Methoxyphenyl)tetrahydro-2H-pyran-4-carbonitrile;4-(4-Methoxyphenyl)oxane-4-carbonitrile
• CAS NO: 3648-78-0
• Molecular Formula: C₁₃H₁₅NO₂
• Molecular Weight: 217.2637
• Mol File: 3648-78-0.mol

Chemical Properties

• Boiling Point: 130 °C(Press: 0.15 Torr)
• Appearance: /
• Density: 1.12±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-(4-Methoxyphenyl)tetrahydro-2H-pyran-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Methoxyphenyl)tetrahydro-2H-pyran-4-carbonitrile(3648-78-0)
• EPA Substance Registry System: 4-(4-Methoxyphenyl)tetrahydro-2H-pyran-4-carbonitrile(3648-78-0)

Safety Data

• Hazardous Substances Data: 3648-78-0(Hazardous Substances Data)

Upstream product

• 5414-19-7 1,1'-oxybis(2-bromo-ethane) 
• 104-47-2 p-methoxybenzylnitrile 
• 111-44-4 3-oxa-1,5-dichloropentane 

Downstream Products

• 868849-45-0 4-(4-hydroxy-phenyl)-tetrahydro-pyran-4-carbonitrile 
• 440087-51-4 1-[4-(4-methoxyphenyl)tetrahydro-2H-pyran-4-yl]-methylamine 
• 3648-58-6 4-(4-methoxyphenyl)-tetrahydro-2-pyran-4-carboxylic acid 
• 4035-86-3 4-(4-methoxyphenyl)tetrahydro-2-pyran-4-carbonyl chloride 
• 885561-38-6 ethyl 4-[(4-methoxyphenyl)tetrahydro-2H-pyran-4-carbonylamino]benzoate 
• 573949-85-6 4-(4-methoxyphenyl)-N-[4-(morpholin-4-ylcarbonyl)-phenyl]tetrahydro-2H-pyran-4-carboxamide 
• 664993-51-5 4-(4-methoxyphenyl)-N-[4-(2-methoxy-5-methylphenylcarbamoyl)phenyl]tetrahydro-2H-pyran-4-carboxamide 
• 694485-33-1 N-{4-[4-(4-methoxyphenyl)tetrahydro-2H-pyran-4-ylmethyl]carbamoylphenyl}benzamide 
• 664993-53-7 N-{4-[4-(4-methoxyphenyl)tetrahydro-2H-pyran-4-ylmethylcarbamoyl]phenyl}furan-2-carboxamide 
• 1035261-19-8 diethyl 2-(4-(4-methoxyphenyl)-tetrahydro-2H-pyran-4-carbonyl)malonate 

Relevant articles and documents

EP300/CREBBP INHIBITOR

The present invention provides a compound having excellent histone acetyltransferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.

New direct inhibitors of InhA with antimycobacterial activity based on a tetrahydropyran scaffold

Tetrahydropyran derivative 1 was discovered in a high-throughput screening campaign to find new inhibitors of mycobacterial InhA. Following initial in-vitro profiling, a structure-activity relationship study was initiated and a focused library of analogs was synthesized and evaluated. This yielded compound 42 with improved antimycobacterial activity and low cytotoxicity. Additionally, the crystal structure of InhA in complex with inhibitor 1 was resolved, to reveal the binding mode and provide hints for further optimization.

Synthesis of p-aminobenzoic acid diamides based on 4-(4-methoxyphenyl)tetrahydro-2H-pyran-4-carboxylic acid and [4-(4-methoxyphenyl)tetrahydro-2H-pyran-4-yl]methylamine

Reaction of 4-(4-methoxyphenyl)tetrahydro-2H-pyran-4-carboxyl chloride with anesthesin followed by hydrolysis of the formed ester has afforded 4-[4-(4-methoxyphenyl)tetrahydro-2H-pyran-4-carbonylamino]benzoic acid. The acid chloride has been used for acyl

NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF

Compounds of Formula (I) and Formula (II) are useful as inhibitors of HIF prolyl hydroxylases. Compounds of Formula(I) and Formula (II) have the following structures, where the definitions of the variables are provided herein.

3- Or 4-monosubstituted phenol derivatives useful as H3 ligands

The invention relates to 3- or 4-monosubstituted phenol derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said 3- or 4-monosubstituted phenol derivatives are H3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

3-[5-substituted benzyl)amino]-2-phenylpiperidines as substance P antagonists

This invention provides a compound of the formula: STR1 and its pharmaceutically acceptable salts, wherein R 1 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, halo C 1 -C 6 alkyl or terahydropyranyl, having one or more substituents selected from cyano, 1,3-thiazolanyl, COOR 2, COR 2, OCOR 2, CONR 3 R 4, NR 3 R 4, NR 5 COR 3 and C.ident.CR 6, wherein R 2 is hydrogen or C 1 -C 4 alkyl, R 3 and R 4 are independently hydrogen, C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl, R 5 is C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl and R 6 is hydrogen, halo, cyano, C 1 -C 6 alkyl, COOH, COO(C 1 -C 4 alkyl) or phenyl; X is C 1 -C 6 alkoxy or halo C 1 -C 6 alkoxy; and Ar is phenyl optionally substituted with halo.These compounds are useful in the treatment of allergic disorders, angiogenesis, gastrointestinal disorders, central nervous system disorders, inflammatory diseases, emesis, urinary incontinence, pain, migraine, sunburn, and diseases, disorders and adverse conditions caused by Helicobacter pylori, in a mammalian subject.